Skip to main content
. 2021 Jan 18;2(1):e12358. doi: 10.1002/emp2.12358

TABLE 2.

Association between receiving over 30 mL IVF/kg of body weight and outcomes for patient enrolled in the PROCESS trial, stratified by ESRD

Models adjusted for sex, race, Charlson Comorbidity score, and APACHE II score
Outcome ESRD a N = 80 Unadjusted ESRD a N = 80 Adjusted Non‐ESRD a N = 1207 Unadjusted Non‐ESRD a N = 1207 Adjusted

  • 90‐day mortality a

  • 0.9 (0.3‐2.6)

  • 1.1 (0.3‐3.9)

  • 1.5 (0.96‐2.2)

  • 1.6 (1.03‐2.6)

  • 60‐day in hospital mortality a

  • 1.2 (0.3‐4.2)

  • 1.57 (0.3‐7.4)

  • 1.4 (0.9‐2.3)

  • 1.4 (0.9‐2.5)

  • 72‐hour intubation a

  • 1.5 (0.5‐4.6)

  • 1.8 (0.4‐7.4)

  • 1.1 (0.8‐1.6)

  • 0.9 (0.6‐1.4)

  • ICU LOS > median of 3 days a

  • 1.3 (0.5‐3.5)

  • 1.4 (0.5‐3.9)

  • 1.2 (0.8‐1.6)

  • 1.27 (0.9‐1.9)

  • Hospital LOS > median of 8 days a

  • 1.4 (0.5‐3.8)

  • 1.3 (0.5‐3.6)

  • 1.3 (0.9‐1.8)

  • 1.2 (0.8‐1.7)
a

Reported as odds ratio (95% confidence interval); compared using univariate logistic regressions for the unadjusted analyses and multivariate logistic regressions for the multivariate analyses.

APACHE, acute physiology and chronic health evaluation; ESRD, end‐stage renal disease; IVF, intravenous fluid; LOS, length of stay; PROCESS, Protocolized Care for Early Septic Shock.